title: The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
abstract: Posttransplant lymphoproliferative disorder (PTLD) is a serious complication in organ transplant recipients and is most often associated with the Epstein Barr virus (EBV). EBV is a common gammaherpes virus with tropism for B lymphocytes and infection in immunocompetent individuals is typically asymptomatic and benign. However, infection in immunocompromised or immunosuppressed individuals can result in malignant B cell lymphoproliferations, such as PTLD. EBV+ PTLD can arise after primary EBV infection, or because of reactivation of a prior infection, and represents a leading malignancy in the transplant population. The incidence of EBV+ PTLD is variable depending on the organ transplanted and whether the recipient has preexisting immunity to EBV but can be as high as 20%. It is generally accepted that impaired immune function due to immunosuppression is a primary cause of EBV+ PTLD. In this overview, we review the EBV life cycle and discuss our current understanding of the immune response to EBV in healthy, immunocompetent individuals, in transplant recipients, and in PTLD patients. We review the strategies that EBV uses to subvert and evade host immunity and discuss the implications for the development of EBV+ PTLD.
authors.affiliation: 1 Division of Abdominal Transplantation and Program in Immunology, Department of Surgery, Stanford University School of Medicine, Stanford, CA.
authors.forename: Olivia M
authors.initials: OM
authors.lastname: Martinez
authors.forename: Sheri M
authors.initials: SM
authors.lastname: Krams
mesh_terms: D000818:Animals; D020031:Epstein-Barr Virus Infections / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity; D054884:Host-Pathogen Interactions; D006801:Humans; D056724:Immunity, Humoral; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007694:Killer Cells, Natural / Q000276:immunology / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D009894:Opportunistic Infections / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D016377:Organ Transplantation / Q000009:adverse effects* / Q000379:methods; D018570:Risk Assessment; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D016896:Treatment Outcome; D014779:Virus Replication
chemical_list: D007166:Immunosuppressive Agents